NEW: European Medicines Agency discourages new Raptiva prescriptions.
Raptiva's product labeling was revised in October to highlight risks.
Raptiva is an injection for adults with moderate to severe plaque psoriasis.
The drug suppresses T-cells, which makes it decrease immune system function.
